LOGO
LOGO

Introgen Therapeutics Sinks In Pre-Market After Filing For Bankruptcy

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Introgen Therapeutics (INGN) eased in pre-market trading, after filing for Chapter 11 petitions in U.S. Bankruptcy Court.

The stock was down 10 cents just before 9:05 am ET, slumping to 14 cents. If pre-market losses hold, the stock will open at its lowest level in a week.

Introgen Therapeutics said that it has elected to file Chapter 11 petitions in the U.S. Bankruptcy Court, Western District of Texas.

Introgen expects that the Chapter 11 process will facilitate the implementation of the company's recently announced strategic reorganization.

As part of this filing, the company is seeking Court approval of a sales procedures motion that will allow Introgen to market its therapeutic portfolio and other assets to prospective buyers.

Introgen expects to continue core activities pertaining to each of its business units during the reorganization process and expects to emerge from Chapter 11 during 2009.

As part of these motions, the company has asked the Court for permission to continue paying employee wages and salaries and to provide employee benefits without interruption.

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Jun 01 - Jun 05, 2026

June 05, 2026 16:18 ET
A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.

Latest Updates on COVID-19